AstraZeneca (AZN +0.13%) may pay a heft dividend, but the company has been facing a number of headwinds and regulatory setbacks lately. In the following video from the Motley Fool's health-care show, Market Checkup, analysts David Williamson and Max Macaluso discuss the partnerships that this company has been forming to boost its pipeline and the key to accelerating its turnaround.
AstraZeneca: Lost Stock or Cheap Turnaround?
By Max Macaluso and Dave Williamson – Sep 19, 2013 at 7:04PM
NASDAQ: AZN
AstraZeneca Plc
Market Cap
$255B
Today's Change
(0.13%) $0.11
Current Price
$82.34
Price as of October 30, 2025 at 4:00 PM ET
Can this big pharma company return to growth?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo